Neuronal differentiation 1 (NeuroD1) (NeuroD1)

Neuronal differentiation 1 (NeuroD1) is a basic helix-loop-helix (bHLH) transcription factor that acts as a master regulator of neurogenesis and pancreatic development [1, 4]. It functions by binding to E-box sequences in the promoter regions of target genes, thereby orchestrating the expression of a vast neuronal gene network essential for the maturation of neurons and the production of insulin in pancreatic beta cells [1, 3]. In the central nervous system, NeuroD1 is critical for the survival and integration of new neurons in the hippocampus and cerebellum [4]. Beyond its developmental role, NeuroD1 has gained significant attention in regenerative medicine for its ability to mediate in vivo reprogramming, converting reactive glial cells into functional neurons to repair brain tissue after injury or neurodegeneration [2]. Mutations in the NEUROD1 gene are clinically linked to Maturity-Onset Diabetes of the Young type 6 (MODY6), emphasizing its importance in metabolic regulation [3]. While there are currently no FDA-approved small molecules targeting NeuroD1, experimental gene therapies using adeno-associated viral (AAV) vectors are being developed to leverage its reprogramming capabilities for treating conditions like Alzheimer's disease and stroke [2]. Additionally, small molecules like isoxazole-9 have been shown to induce NeuroD1 expression in neural stem cells, offering a potential pharmacological route for neuroregeneration. The target's dual role in the brain and pancreas makes it a complex but promising focus for both metabolic and neurological therapeutic strategies.

Other names

NeuroDBHF-1bHLHa3Beta2NEUROD1

Acts as a transcriptional activator by binding to E-box motifs (5'-CANNTG-3') in the promoters of neuronal and pancreatic genes; promotes the conversion of non-neuronal cells into neurons through epigenetic and transcriptional reprogramming [1, 2].